Background New research criteria for preclinical Alzheimer's disease have been proposed, which include stages for cognitively normal individuals with abnormal amyloid markers (stage 1), abnormal amyloid and neuronal injury markers (stage 2), or abnormal amyloid and neuronal injury markers and subtle cognitive changes (stage 3). We aimed to investigate the prevalence and long-term outcome of preclinical Alzheimer's disease according to these criteria.
Introduction
Alzheimer's disease (AD) starts with a preclinical phase in which AD neuropathological abnormalities begin to accumulate but cognitive ability is normal. [1] [2] [3] Now that biomarkers for AD have become available, identifi cation of preclinical AD in vivo in cognitively normal individuals is possible. 4 Information regarding the occurrence and outcome of preclinical AD is crucial for the understanding of AD pathophysiology and the design of secondary prevention trials.
Research criteria for preclinical AD have been proposed by the Preclinical Working Group of the National Institute on Aging (NIA) and Alzheimer's Association (AA). 5 The NIA-AA criteria for preclinical AD propose ordered stages for cognitively normal individuals with abnormal amyloid markers (stage 1), abnormal amyloid and neuronal injury markers (stage 2), and abnormal amyloid and neuronal injury markers and subtle cognitive changes (stage 3). 5 In a 2012 study in which structural and amyloid imaging markers were used to categorise individuals according to these stages, 6 the rate of short-term (1 year) progression to mild cognitive impairment (MCI) or dementia increased with advancing preclinical AD stage.
The aim of this study was to identify the prevalence and long-term outcome of preclinical AD according to these criteria in a cohort of cognitively normal individuals. We used CSF markers to defi ne NIA-AA preclinical AD stages and assessed the long-term cognitive and mortality outcomes of participants in each stage. We also tested whether the proportion and cognitive outcome of preclinical AD were aff ected by age or APOE genotype. ageing at the Knight Alzheimer's Disease Research Center (KADRC) of the Washington University School of Medicine (St Louis, MO, USA). Details of recruitment and assessment methods for these participants have been published. 7 Participants in the KADRC cohort were living independently in the community at study entry and underwent annual clinical assessment unless prevented by death, illness, refusal, or relocation from St Louis. Participants were selected from the larger KADRC cohort based on the following criteria: completion of baseline cognitive and CSF assessment; baseline clinical dementia rating (CDR) score of 0; at least 65 years of age at the time of lumbar puncture; at least one annual clinical follow-up assessment; and good general health. The Human Research Protection Offi ce at Washington University School of Medicine approved the KADRC studies, including the Healthy Aging and Senile Dementia study (P01AG003991), the Alzheimer's Disease Research Center study (P50AG05681), and the Antecedent Biomarkers for AD: the Adult Children Study (P01-AG026276). Written informed consent was obtained from all participants at enrolment.
Procedures
Participants underwent annual cognitive assessment, which included CDR and CDR sum of boxes (CDR-SB), 8 mini-mental state examination (MMSE), and a psychometric test battery. 9 The CDR is a global dementia staging system that assesses the presence or absence of dementia and, when present, its severity. The global CDR stages are 0, indicating cognitive normality, and 0·5, 1, 2, and 3, indicating very mild impairment or very mild dementia, and mild, moderate, and severe dementia, respectively. 10 The CDR-SB is a more quantitative representation of cognitive impairment than the global CDR and is derived directly from individual ratings in six cognitive and functional domains, or boxes (memory, orientation, judgment and problem solving, community aff airs, home and hobbies, and personal care). The CDR-SB is the total score of all the separate boxes (range 0-18, with 0 as the best score). Participants with a CDR score of 0 typically have scores of 0 on all box scores; however, a global CDR score of 0 can also be assigned in the presence of one box score of 0·5 in a non-memory domain. Baseline CDR score and diagnosis were assigned by trained clinicians and were based on the cognitive assessment closest to the time of the lumbar puncture.
We used CSF markers to defi ne NIA-AA preclinical AD stages. CSF amyloid-β 1-42 (Aβ 1-42 ) was used as a marker of amyloid and CSF tau was used as a marker of neuronal injury. CSF samples (20-25 mL) were collected once at study entry at 0800 h after overnight fasting. Lumbar punctures (lumbar vertebrae L4/L5) were done by trained neurologists using a 22-gauge atraumatic Sprotte spinal needle (Pajunk Medical Systems, Norcross, GA, USA). Samples were gently inverted to avoid possible gradient eff ects, briefl y centrifuged at low speed, and aliquoted (0·5 mL) into polypropylene tubes before being frozen at −84°C. Samples were analysed for total tau (t-tau), phosphorylated tau 181 (p-tau 181 ), and Aβ 1-42 by ELISA (INNOTEST; Innogenetics, Ghent, Belgium).
CSF markers were dichotomised (normal or abnormal) by defi ning a cutoff that could best diff erentiate participants in our cohort who had CDR 0 at baseline from those in an independent cohort who had CDR 0·5, symptomatic AD (for demographics of this cohort, see appendix), on the basis of the Youden index (sensitivity+specifi city-1). The resultant optimum cutoff s for abnormal were less than 459 pg/mL for Aβ 1-42 , greater than 339 pg/mL for t-tau, and greater than 67 pg/mL for p-tau 181 .
The NIA-AA criteria for preclinical AD do not defi ne the subtle cognitive changes needed for classifi cation as stage 3. Since episodic memory is usually the earliest cognitive domain to be aff ected in AD, 11, 12 we used an episodic memory composite score as the measure of cognition to defi ne stage 3. The composite score was based on factor analyses 9 and consisted of the sum of the three free recall trials from the Buschke free and cued selective reminding test, 13 total scores from the easy and hard trials of associate learning from the Wechsler memory scale-revised, 14 and the total number of correctly recalled units from the Wechsler memory scale-revised logical memory immediate recall test. Raw scores from each test were converted to Z scores using a normative reference sample of participants from the KADRC who were cognitively normal at enrolment and who did not progress to a dementia diagnosis during follow-up (ie, remained CDR 0). 15 The normative reference sample, as described in detail by Johnson and colleagues, 15 was composed of participants who were enrolled in ongoing studies at the KADRC between Oct 1, 1979, and Dec 31, 2006 . 82 (26%) of the 311 participants in the present study contributed cognitive scores (almost exclusively from annual visits before CSF collection) to the normative reference sample. The mean of the three tests was used to create a composite episodic memory score and was converted again into a Z score within the population. The cutoff at the lowest tenth percentile of the distribution in our sample (less than -1·25 SD) was applied to signify memory impairment.
At baseline, participants were classifi ed as normal if both episodic memory and CSF markers met our criteria for normal, in stage 1 if only Aβ 1-42 was abnormal, in stage 2 if Aβ 1-42 and either t-tau or p-tau 181 were abnormal, and in stage 3 if additionally the participant's cognitive ability was below the memory test threshold (panel 1). Participants were classifi ed in the suspected nonAlzheimer pathophysiology (SNAP) group if they had abnormal t-tau or p-tau 181 in the presence of normal Aβ 1-42 , regardless of episodic memory ability (panel 1). 16 Participants who did not fi t within one of the groups were included in the unclassifi ed group and, in view of the uncertainty of their classifi cation, were excluded from the main analyses.
See Online for appendix
The primary outcome measure was the proportion of participants in each preclinical AD stage, as defi ned by CSF markers and scores on episodic memory tests. Secondary outcome measures were cognitive decline on the CDR-SB and MMSE, progression to CDR at least 0·5, symptomatic AD at the latest available follow-up before dropout, and mortality.
In our KADRC research cohort, the clinical diagnosis of AD in individuals with a CDR score of 0·5 or greater is based on criteria from the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association, 17 in accordance with standard protocols. 7 In individuals with a CDR score of 0·5, AD was diagnosed if a score of at least 0·5 was given for memory and at least one other domain and the clinician deemed the cognitive impairments to be due to AD (probable AD; referred to as CDR 0·5, symptomatic AD). CDR 0·5, symptomatic AD diff ers from MCI as defi ned in the criteria of MCI due to AD or prodromal AD, 18, 19 although it is similar (appendix). As part of the assessment to defi ne whether a participant was cognitively impaired with or without symptomatic AD, a thorough, informant-based and participant-based interview was completed. Cognitive examination, consisting of assessment of recent and long-term memory, executive function, reasoning, language, and visuospatial function, was also undertaken by trained clinicians. The CDR rating and diagnosis are based on both present and historical cognitive ability. In contrast to MCI, an absolute cutoff score on a specifi c cognitive test is not used to defi ne the presence of cognitive impairment. Moreover, classifi cation as CDR 0·5, symptomatic AD requires clinical change in two cognitive domains, whereas subjective complaints and impairment in any cognitive domain is suffi cient to meet the criteria for MCI (appendix).
In a subset of participants for whom autopsy samples were available, neuropathological examination was undertaken using established protocols. 20 AD neuropathological changes were rated using the NIA-AA guidelines. 21 We also tested whether the prevalence and long-term outcome of preclinical AD were aff ected by age or APOE genotype. TaqMan assays (Applied Biosystems, Foster City, CA, USA) for both ABI#C_3084793_20 and ABI#C_904973_10 were used for APOE genotyping, as described previously.
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Statistical analysis
Baseline diff erences between the stages were analysed using ANOVA for continuous variables and Fisher's exact tests and logistic regression models for categorical variables. Missing data from cognitive tests at follow-up were modelled with mixed models. We fi rst undertook an omnibus test for joint signifi cance of the stage variables and proceeded with subgroup analyses only if this overall test was statistically signifi cant. We did competing-risks survival analyses using Fine and Gray's 23 subdistribution hazards model (subdistribution hazards ratio [SHR] ) to investigate the predictive accuracy of the preclinical AD stages for progression to CDR at least 0·5, symptomatic AD during the available follow-up period, with normal individuals as a reference group, uncorrected and corrected for baseline age, sex, education, and APOE genotype. Unlike standard Cox hazards models that usually treat mortality as censoring, these models regard mortality as a competing event that can impede progression to symptomatic AD. Standard Cox proportional hazards models (hazard ratio [HR]) were used to assess the predictive capacity of preclinical AD stages for mortality during the follow-up period, in both unadjusted and adjusted analyses. The relation between the stages and rate of change in CDR-SB and MMSE over time were assessed with general linear mixed models including linear time eff ects, 24 adjusted for baseline age, sex, education, and APOE genotype. Analyses included baseline score and all available follow-up scores. The fi nal models were specifi ed with a random intercept and slope, because these models provided the best measures on Akaike's information criterion 25 for analysis of the corresponding clinical and cognitive measures compared with models with other covariance structures. Specifi c values for each covariate were used to create adjusted plots for the survival analyses and mixed models. Predicted curves or slopes for each of Unclassifi ed group CDR 0 (no dementia), with or without amyloid, no neuronal injury, subtle cognitive decline Symptomatic AD CDR>0, memory and at least one other domain received a score of ≥0·5 and the clinician felt the cognitive impairments to be due to AD (probable AD according to NINDS-ADRDA criteria), no reference to biomarkers AD=Alzheimer's disease. No amyloid=CSF amyloid-β 1-42 (Aβ 1-42 ) ≥459 pg/mL. Amyloid=CSF Aβ 1-42 <459 pg/mL. CDR 0=clinical dementia rating score of 0, no dementia. CDR 0·5=very mild impairment or very mild dementia. CDR 1=mild dementia. CDR 2=moderate dementia. CDR 3=severe dementia. No neuronal injury=CSF total tau (t-tau) ≤339 pg/mL and phosphorylated tau 181 (p-tau 181 ) ≤67 pg/mL. Neuronal injury=CSF t-tau >339 pg/mL or p-tau 181 >67 pg/mL. SNAP=suspected non-Alzheimer pathophysiology. Subtle cognitive decline=episodic memory composite score in the lowest 10th percentile. No subtle cognitive decline=episodic memory composite score in the highest 90th percentile.
the AD stage groups were plotted within each combination of APOE ε4 and sex with age (72·6 years) and education (15·5 years) fi xed at the sample means. These means represent the total group of participants, excluding the unclassifi ed group because this group was not included in these analyses. Subdistribution hazards models were implemented using the STCRREG command in STATA 12 (Stata, College Station, TX, USA). All other statistical analyses were done with SPSS version 19.0 (Chicago, IL, USA), with signifi cance set at p<0·05.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all data in the study and had fi nal responsibility for the decision to submit for publication. (table 1) . Preclinical AD (stage 1-3) was more prevalent in individuals older than 72 years (median age of sample) than in those aged 72 years or younger (37% vs 26%; p=0·044) and was more prevalent in APOE ε4 carriers than in non-carriers (47% vs 23%; p<0·0001; appendix). The mean interval between lumbar puncture and the closest cognitive assessment was 2·6 months (SD 2·1). 110 (35%) participants were available at 5 years of follow-up and 14 (5%) were available at 10 years. 39 patients (13%) were lost to follow-up and 20 (6%) died during follow-up. After a median follow-up of 3·9 years (range 1-15), progression to CDR at least 0·5, symptomatic AD had occurred in two (2%) participants in the group classed as normal, six (13%) in stage 1, nine (25%) in stage 2, seven (54%) in stage 3, four (6%) in the SNAP group, and four (29%) in the unclassifi ed group (table 2) . Of the 32 participants who progressed, 22 (69%) were diagnosed with CDR 0·5, symptomatic AD at their last follow-up, six (19%) had CDR 1, symptomatic AD, and four (13%) had CDR 2, symptomatic AD.
Results
Survival analyses showed that, taking into account mortality, participants in each preclinical AD stage had a higher risk of progression to CDR at least 0·5, symptomatic AD than did participants classed as normal (stage 1 SHR 7·0, 95% CI 1·4-34·1, p=0·016; stage 2 SHR 18·1, 3·9-83·1, p=0·0002; stage 3 SHR 49·2, 10·1-240·4, p<0·0001; table 2, fi gure). Preclinical AD stages also diff ered from each other, with more severe stages associated with higher risk of progression to symptomatic AD, although the diff erence between stages 2 and 3 was not signifi cant (p=0·066). The progression rate of participants in the SNAP group did not diff er from that of individuals classed as normal (p=0·20). Only plots for APOE ε4 negative women are shown because this is the most populous group of the four combinations from the two dichotomous factors, APOE ε4 and sex. However, eff ects of preclinical AD stages (either on risk of converting to a higher CDR or on rate of change in MMSE) remained the same regardless of the combinations of APOE ε4 and sex. After correction for covariates, results remained essentially the same, except that progression in stage 1 was no longer diff erent from that of individuals classed as normal (SHR 4·6, 95% CI 0·8-25·6, p=0·079), which was mainly driven by the correction for age (data not shown). The estimated 5-year progression (cumulative incidence) rate to CDR at least 0·5, symptomatic AD was 2% for participants classed as normal, 11% for those in stage 1, 26% for those in stage 2, 56% for those in stage 3, and 5% for those in the SNAP group. The risk of progression was not diff erent between older (>72 years) and younger (≤72 years) individuals with preclinical AD (SHR 2·0, 95% CI 0·7-5·5; p=0·19) or between APOE ε4 carriers and non-carriers with preclinical AD (SHR 1·1, 0·5-2·6, p=0·76; appendix). 20 (6%) participants died during follow-up (table 1) . Compared with individuals classed as normal, participants with preclinical AD (stage 1-3) had an increased risk of death after adjusting for covariates (HR 6·2, 95% CI 1·1-35·0; p=0·040), which increased with advancing stage (table 2). There was weak evidence of a diff erence in risk of death in the SNAP group compared with the normal group (HR after adjustment 5·2, 95% CI 0·9-30·9; p=0·071). Of the nine participants with preclinical AD who underwent autopsy, eight received a neuropathological diagnosis of AD with intermediate-to-high neuro pathological AD change and one received a diagnosis of AD with low neuropathological AD change (table 3) . Three of four participants with SNAP who underwent autopsy had low level neuropathological AD change according to 
A Uncorrected
B Corrected
NIA-AA criteria; thus this pathological change is unlikely to explain the cognitive impairments. Of these three individuals with SNAP, two were in NIA-AA Aβ stage 1 and one was in NIA-AA Aβ stage 2 but this individual had a low neurofi brillary tangle score and vascular comorbidity. 21 All participants with SNAP had a neuritic plaque score of 0. Other coexisting pathological abnormalities in these individuals were minor and were deemed unlikely to have contributed substantially to the cognitive status. The time to death after baseline lumbar puncture ranged from 2 to 11 years for all participants; therefore, AD pathology might have accumulated by the time of autopsy. 
Discussion
In this study, we show that preclinical AD can be defi ned by CSF markers, is common in individuals aged at least 65 years, and is associated with an increased risk of cognitive decline, progression to CDR at least 0·5, symptomatic AD, and mortality (panel 2). 31% of participants in our cohort had preclinical AD (stages 1-3), which is consistent with fi ndings from clinicopathological studies 1-3 and the population-based Mayo Clinic Study of Aging (MCSA), which used imaging measures (appendix). 16 The validity of our biomarkerbased diagnosis of preclinical AD was further supported by the fi nding that eight of nine participants with preclinical AD who underwent autopsy had intermediateto-high AD neuropathological changes. The distribution across the preclinical AD stages was also similar to that reported in the MCSA. 16 Individuals with preclinical AD progressed faster to CDR at least 0·5, symptomatic AD than did those in the normal and SNAP groups. Progression rates diff ered between the preclinical AD stages; thus, stages 1, 2, and 3 represent diff erent and progressive disease severities. Findings from the MCSA also showed an increased rate of cognitive decline with advancing stage, although only 1 year of follow-up data were reported. 6 Mortality risk was higher in participants with preclinical AD than in those in the normal group and also increased with advancing stage. To our knowledge, no other studies have examined mortality risk in preclinical AD, but our fi ndings are consistent with clinical studies in individuals with incident or very mild AD dementia. 26, 27 There is no clear explanation for the increased mortality risk. Risk factors for AD might also be associated with other lifethreatening diseases. Alternatively, AD-related cognitive impairments might increase mortality risk because they may hamper diagnosis and management of other diseases or increase the risk of accidents. 28, 29 Increased mortality risk might also have resulted from AD pathological abnorm alities, which might compromise the physiological response to other illnesses. 30 However, further research is needed to understand the relation between preclinical AD and mortality.
The proportion of participants with preclinical AD was higher in older individuals and in APOE ε4 carriers than in younger individuals and non-carriers, which is in line with fi ndings from previous studies. 31 However, neither age (<72 years vs ≥72 years) nor APOE genotype predicted rate of decline, although these subanalyses had limited statistical power owing to the small sample sizes. Although APOE ε4 is often a good predictor of cognitive decline in unselected populations, the absence of its prognostic utility in individuals with AD pathological abnormalities is consistent with fi ndings from previous studies.
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23% of participants in this study had SNAP, in line with fi ndings from the MCSA. 16 Cognitive decline in the SNAP group was similar to that in normal individuals, although there was weak evidence of increased mortality. There were no to low AD pathological changes on autopsy, suggesting that these individuals might have other diseases.
The selection of cutoff s is crucial for categorisation of NIA-AA stages. 5 We used the Youden index to defi ne the CSF cutoff s. These values were lower than those previously used in a similar cohort (Aβ 1-42 <500 pg/mL, t-tau >440 pg/mL, and p-tau 181 >78 pg/mL). 33 Use of the previous cutoff s would lead to a slightly higher proportion of preclinical AD (40%), but the progression to symptomatic AD remained the same (appendix). Our cognitive cutoff at the tenth percentile was in line with that used in the MCSA. 6, 16 Also, the choice of cognitive tests might aff ect the NIA-AA staging and outcome. We defi ned subtle cognitive changes as low scores on a memory composite test. If subtle cognitive change was defi ned as a low score in any cognitive domain (episodic memory, semantic memory, working memory, or visuospatial score, as described by Johnson and colleagues 15 ), the number of individuals in stage 3 and the unclassifi ed group would increase. However, progression rates to CDR at least 0·5, symptomatic AD in these groups would be lower (appendix). Although we used a composite score of three memory tests on the basis of factor analyses, the use of a specifi c memory test could have led to diff erent results.
Participants in stage 3 diff ered from those with MCI or early dementia in that they had a CDR score of 0 and therefore no change in cognitive function and no interference in activities of daily living. Still, some of these participants might have met psychometric criteria for MCI. Findings from a study in autosomal dominant AD mutation carriers 34 showed that individuals with preclinical AD might have cognitive impairments without disturbance in functional abilities, and thus appear clinically normal. 14 participants remained unclassifi ed and their outcome has not been investigated previously. They had an increased risk of progression to symptomatic AD but not of mortality compared with the normal group (appendix). Although amyloid pathology might be present in these individuals, future studies are needed to clarify their characteristics and outcome.
Our results are consistent with those recently reported in the MCSA, 6, 16 although there were important diff erences in study design. The MCSA used imaging markers for staging individuals and cognitive tests to defi ne clinical diagnosis rather than the CDR. Furthermore, the biomarker cutoff s were defi ned as those yielding 90% sensitivity for diagnosing AD dementia from a separate AD cohort and a global cognitive test score was used to defi ne subtle cognitive change. The similarity in fi ndings between the studies suggests that CSF and imaging markers might be equally eff ective for identifi cation of individuals with preclinical AD and prediction of clinical outcome. However, this suggestion does not imply that CSF and imaging makers are equivalent. Head-to-head comparison might yield a diff erent conclusion.
The major strengths of this study are the large sample size of well-characterised participants and the long followup period of up to 15 years (mean 4 years). However, our study has several limitations. Because participants agreed to take part in a longitudinal study, including multiple neuroimaging procedures and serial lumbar punctures, they are unlikely to be representative of the general population; nor were they selected at random from the population. However, our sample is similar to other research samples of cognitively normal older adults and people with early symptomatic AD. 35 Also, the number of participants who progressed to symptomatic AD in each stage was small and results should therefore be interpreted carefully. Furthermore, AD clinical diagnosis at follow-up was neuropathologically validated in only a small subset of participants. Thus, some participants might have been misclassifi ed, although the rate of confi rmation of AD diagnosis post mortem at the KADRC is high (93%). 7 Similar to participants in the MCSA, participants in our study were mainly white and highly educated, and fi ndings might not apply to individuals with other backgrounds. Although we included cognitively normal individuals (CDR 0), 18 of them had a CDR-SB score of 0·5 (one score of 0·5 in a non-memory domain) and could be considered suspicious because these people might not be truly unimpaired. However, analyses without these participants revealed similar results (appendix).
Although we regard this study as preliminary and hypothesis generating, our fi ndings have several important implications. First, these fi ndings show that preclinical AD is common and can be diagnosed by CSF markers, as shown by neuropathological validation in eight of nine participants who underwent autopsy. The strong association between preclinical AD and future cognitive decline and mortality makes preclinical AD an important target for therapeutic intervention. Second, they show that the proposed NIA-AA staging of preclinical AD represents diff erent disease stages in view of diff erences in rate of progression. Third, the fi ndings from this study have implications for the design of secondary prevention trials. Screening of individuals for biomarker assessment according to their age and APOE genotype might be useful, and trials could stratify individuals by preclinical AD stage. The rate of cognitive decline was low compared with that in individuals with MCI 36 or dementia. 37 Thus, trials of preclinical AD need large sample sizes or a longer follow-up to identify eff ects on cognitive outcome measures. Furthermore, mortality should be considered as an endpoint in trials. Fourth, both occurrence and outcome of preclinical AD are dependent on tests and CSF cutoff s used, which highlights the need for standardisation.
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Confl icts of interest
Systematic review
We searched PubMed up to April, 2013, with no date limits set, with the terms "preclinical", "Alzheimer's disease", "cerebrospinal fl uid", "amyloid", "tau", "NIA-AA", "cognition", "autopsy", and "mortality". We included studies that assessed preclinical Alzheimer's disease (AD) and its outcome. We assessed reports on amyloid-β 1-42 (Aβ 1-42 ) and tau in CSF in which cognitive decline and AD-type dementia were primary outcome measures. Systematic review of the literature showed that AD pathological changes start long before clinical symptoms appear, and that CSF Aβ 1-42 and tau are well-established biomarkers for the disease. A recent study on staging of preclinical AD according to the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria using imaging markers found that short-term cognitive decline increased with advancing preclinical AD stage. 17 To the best of our knowledge, no study has been done on the NIA-AA staging of preclinical AD using CSF markers and long-term cognitive outcome, or on mortality risk in preclinical AD.
Interpretation
In this study, we show that preclinical AD is common in individuals over the age of 65 years and can be identifi ed by Aβ 1-42 and tau in CSF, as shown by neuropathological validation in eight of nine participants who underwent autopsy. Our fi ndings show that the proposed NIA-AA staging of preclinical AD represents diff erent disease stages, in view of diff erences in rate of progression to symptomatic AD and in decline on continuous measures of function and global cognition. Furthermore, participants with preclinical AD had a higher mortality risk than those in the normal group, which also increases with advancing stage. The association between preclinical AD and future cognitive decline and mortality makes preclinical AD an important target for therapeutic intervention.
